IDYA — IDEAYA Biosciences, Inc.

Is IDYA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of October 3, 2026

IDEAYA Biosciences, Inc. (IDYA) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $37.36. The rating moved from Oversold to Neutral on September 30, 2026.

AI analysis

IDEAYA Biosciences, Inc. (IDYA) is a precision oncology-focused biotech with DDR-oriented programs and partner-enabled development pathways. The company benefits from differentiated science and partner optionality that can reduce execution risk and provide strategic funding routes. Near-term upside depends on clinical readouts, partnership announcements, and capital markets receptivity; conversely, binary clinical/regulatory outcomes and potential dilution remain primary downside drivers.

Key factors

  • Pipeline focus on precision oncology and DNA damage response (DDR) mechanisms provides differentiated scientific exposure and potential high-value readouts.
  • Strategic collaborations and licensing deals (historical partner support and co-development optionality) that can de-risk funding needs and accelerate commercialization paths for selected assets.
  • Market interest in late-stage/specialty biotech assets remains present despite risk-off environment, supporting secondary liquidity and M&A/partnering optionality.
  • Valuation reflects clinical and regulatory binary risks; current price implies upside if upcoming catalysts (trial readouts, regulatory milestones, or partnership expansions) are positive.
  • Limited near-term macro catalysts and defensive market tone have compressed biotech multiples; this creates a potential re-rating opportunity if company-specific news contrasts with sector weakness.
  • Relative insulation from GLP-1 competitive dynamics; core therapeutic focus is oncology/DDR rather than high-volume metabolic therapies, reducing direct product-market competition from that theme.

Risks

  • Clinical trial failures or missed endpoints in key programs leading to sharp valuation declines due to binary nature of readouts.
  • Funding and dilution risk if cash runway is insufficient and capital markets remain muted; potential for equity raises at lower prices.
  • Regulatory setbacks or slower-than-expected approval timelines that delay commercialization and revenue generation.
  • Downward pricing pressure and access risk from Medicare drug‑price negotiation and payer cost-containment measures that could impact eventual pricing and uptake.
  • Broader biotech risk-off market dynamics and reduced IPO/secondary issuance appetite that can exacerbate share price volatility unrelated to fundamentals.
  • Competition from other DDR-targeting programs, combination regimens, or alternative oncology modalities that could limit market share or clinical differentiation.
  • Operational execution risk including manufacturing, trial enrollment delays (global supply chain/geopolitical effects), or partnership disputes.

See today's live rating, score and targets

Members see the live hourly rating for IDYA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.